Best Recession-Proof Stocks to Buy in 2026
Defensive companies with stable earnings, low debt, and proven resilience — ranked by quality score.
| # | Ticker | Company | Price | 1D | Quality | Valuation | Market Cap |
|---|---|---|---|---|---|---|---|
| 1 | ORNBV.HE | Orion Oyj | $71.70 | -0.1% | 100 | — | $10.1B |
| 2 | ZTS | Zoetis Inc. | $117.94 | +0.6% | 100 | Undervalued | $52.0B |
| 3 | RMD | ResMed Inc. | $224.09 | +0.6% | 100 | Undervalued | $32.7B |
| 4 | PRX.AS | Prosus N.V. | $40.02 | -1.3% | 100 | — | $86.5B |
| 5 | CPRX | Catalyst Pharmaceuticals, Inc. | $24.69 | -0.5% | 100 | Undervalued | $3.0B |
| 6 | TGTX | TG Therapeutics, Inc. | $33.53 | -0.1% | 100 | Undervalued | $5.4B |
| 7 | DOCS | Doximity, Inc. | $22.77 | -0.7% | 100 | Deeply Undervalued | $4.3B |
| 8 | EXEL | Exelixis, Inc. | $43.88 | -0.4% | 100 | Undervalued | $11.8B |
| 9 | INCY | Incyte Corporation | $95.93 | +1.7% | 100 | Undervalued | $19.1B |
| 10 | NBIX | Neurocrine Biosciences, Inc. | $131.60 | -0.7% | 100 | Undervalued | $13.2B |
| 11 | VRTX | Vertex Pharmaceuticals Incorporated | $438.71 | -1.9% | 100 | Undervalued | $111.4B |
| 12 | UTHR | United Therapeutics Corporation | $564.81 | -1.0% | 100 | Undervalued | $24.8B |
| 13 | HALO | Halozyme Therapeutics, Inc. | $64.49 | -1.4% | 100 | Deeply Undervalued | $7.6B |
| 14 | LOPE | Grand Canyon Education, Inc. | $171.36 | +0.1% | 100 | Undervalued | $4.8B |
| 15 | VEEV | Veeva Systems Inc. | $173.98 | +0.7% | 100 | Undervalued | $28.6B |
| 16 | CALM | Cal-Maine Foods, Inc. | $78.10 | -6.3% | 95 | Deeply Undervalued | $3.7B |
| 17 | MRK | Merck & Co., Inc. | $120.87 | +0.0% | 95 | Undervalued | $298.8B |
| 18 | NEE | NextEra Energy, Inc. | $93.15 | +0.3% | 95 | Undervalued | $194.1B |
| 19 | OTTR | Otter Tail Corporation | $88.59 | +0.4% | 95 | Overvalued | $3.7B |
| 20 | AWK | American Water Works Company, Inc. | $138.14 | +1.0% | 95 | Undervalued | $27.0B |
| 21 | GILD | Gilead Sciences, Inc. | $139.71 | -0.4% | 95 | Undervalued | $173.4B |
| 22 | LLY | Eli Lilly and Company | $935.58 | -2.0% | 95 | Deeply Overvalued | $837.4B |
| 23 | REGN | Regeneron Pharmaceuticals, Inc. | $761.85 | -2.0% | 95 | Undervalued | $80.5B |
| 24 | GMED | Globus Medical, Inc. | $87.92 | +0.2% | 95 | Undervalued | $11.9B |
| 25 | ILMN | Illumina, Inc. | $127.38 | +0.6% | 95 | Undervalued | $19.5B |
| 26 | LGND | Ligand Pharmaceuticals Incorporated | $199.59 | -0.0% | 95 | Undervalued | $4.0B |
| 27 | BIO | Bio-Rad Laboratories, Inc. | $279.99 | +0.6% | 95 | Undervalued | $7.6B |
| 28 | EW | Edwards Lifesciences Corporation | $81.05 | -0.3% | 95 | Undervalued | $47.1B |
| 29 | NOVO-B.CO | Novo Nordisk A/S | $236.90 | +2.6% | 90 | — | $1.1T |
| 30 | EIX | Edison International | $73.46 | -0.2% | 90 | Undervalued | $28.3B |
| 31 | WTRG | Essential Utilities, Inc. | $41.08 | +1.1% | 90 | Undervalued | $11.6B |
| 32 | NOVN.SW | Novartis AG | $123.20 | +0.2% | 90 | — | $235.1B |
| 33 | AMGN | Amgen Inc. | $347.94 | -1.5% | 90 | Undervalued | $187.6B |
| 34 | SWX | Southwest Gas Holdings, Inc. | $89.24 | +2.0% | 90 | Undervalued | $6.5B |
| 35 | KO | The Coca-Cola Company | $76.72 | +0.8% | 90 | Fair Value | $330.2B |
| 36 | ATO | Atmos Energy Corporation | $188.97 | +1.9% | 90 | Undervalued | $31.3B |
| 37 | JNJ | Johnson & Johnson | $243.04 | -0.4% | 90 | Undervalued | $585.7B |
| 38 | RPRX | Royalty Pharma plc | $48.57 | +0.2% | 90 | Undervalued | $28.1B |
| 39 | IRDM | Iridium Communications Inc. | $32.86 | +15.2% | 90 | Undervalued | $3.4B |
| 40 | ROG.SW | Roche Holding AG | $318.00 | -0.1% | 90 | — | $256.4B |
| 41 | DXCM | DexCom, Inc. | $62.22 | -0.2% | 90 | Undervalued | $24.3B |
| 42 | BIIB | Biogen Inc. | $177.34 | -3.5% | 90 | Undervalued | $26.0B |
| 43 | HQY | HealthEquity, Inc. | $84.67 | +1.6% | 90 | Undervalued | $7.2B |
| 44 | BMRN | BioMarin Pharmaceutical Inc. | $55.50 | -3.0% | 90 | Undervalued | $10.7B |
| 45 | HOLX | Hologic, Inc. | $75.65 | +0.1% | 90 | Undervalued | $16.9B |
| 46 | LNTH | Lantheus Holdings, Inc. | $76.10 | +0.5% | 90 | Undervalued | $5.0B |
| 47 | FIZZ | National Beverage Corp. | $33.75 | -0.3% | 90 | Undervalued | $3.2B |
| 48 | MEDP | Medpace Holdings, Inc. | $498.34 | +1.8% | 90 | Undervalued | $14.1B |
| 49 | WAT | Waters Corporation | $304.24 | +1.4% | 90 | Fair Value | $29.8B |
| 50 | BMY | Bristol-Myers Squibb Company | $59.60 | -2.5% | 85 | Undervalued | $121.7B |
AI-generated screening for informational purposes only. Not investment advice. Data updated daily.